No connection

Search Results

NRIX vs OMCL

NRIX
Nurix Therapeutics, Inc.
NEUTRAL
Price
$16.30
Market Cap
$1.69B
Sector
Healthcare
AI Confidence
80%
OMCL
Omnicell, Inc.
NEUTRAL
Price
$37.53
Market Cap
$1.71B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
NRIX
--
OMCL
938.25
Forward P/E
NRIX
-5.73
OMCL
17.98
P/B Ratio
NRIX
3.5
OMCL
1.37
P/S Ratio
NRIX
23.48
OMCL
1.44
EV/EBITDA
NRIX
-3.92
OMCL
37.6

Profitability

Gross Margin
NRIX
0.0%
OMCL
42.88%
Operating Margin
NRIX
-1479.45%
OMCL
2.2%
Profit Margin
NRIX
0.0%
OMCL
0.17%
ROE
NRIX
-61.4%
OMCL
0.17%
ROA
NRIX
-31.5%
OMCL
0.36%

Growth

Revenue Growth
NRIX
-66.1%
OMCL
2.3%
Earnings Growth
NRIX
--
OMCL
--

Financial Health

Debt/Equity
NRIX
0.12
OMCL
0.17
Current Ratio
NRIX
6.01
OMCL
1.43
Quick Ratio
NRIX
5.89
OMCL
0.9

Dividends

Dividend Yield
NRIX
--
OMCL
--
Payout Ratio
NRIX
0.0%
OMCL
0.0%

AI Verdict

NRIX NEUTRAL

NRIX exhibits a severe fundamental disconnect, characterized by a critical Piotroski F-Score of 1/9, indicating very weak financial health. While the company maintains a strong liquidity position with a current ratio of 6.01 and low debt, the -66.10% YoY revenue collapse and negative operating margins are alarming. The stock is currently driven by speculative momentum and a strong analyst consensus (Target $30.24) rather than deterministic value, as evidenced by the bearish insider selling and a high Price/Sales ratio of 23.48.

Strengths
Strong short-term liquidity (Current Ratio: 6.01)
Very low leverage (Debt/Equity: 0.12)
Strong analyst conviction (Strong Buy recommendation from 17 analysts)
Risks
Critical financial health deterioration (Piotroski F-Score: 1/9)
Severe revenue contraction (-66.10% YoY)
Extreme operating inefficiency (Operating Margin: -1479.45%)
OMCL NEUTRAL

OMCL presents a stark contrast between strong financial health and poor valuation metrics. While the Piotroski F-Score of 7/9 indicates a strong operational baseline and the balance sheet is lean with a Debt/Equity ratio of 0.17, the stock trades at a massive premium to its Graham Number ($4.96) and Intrinsic Value ($0.28). The astronomical trailing P/E of 938.25 is offset by a reasonable Forward P/E of 17.98, suggesting the market is pricing in a significant earnings recovery. However, razor-thin profit margins (0.17%) and bearish insider activity temper the strong analyst 'Strong Buy' consensus.

Strengths
Strong Piotroski F-Score (7/9) indicating operational health
Very low leverage with a Debt/Equity ratio of 0.17
Strong analyst consensus with a target price of $57.43
Risks
Extreme trailing P/E ratio (938.25) indicating severe overvaluation based on current earnings
Negligible profit margins (0.17%) leaving no room for operational error
Bearish insider sentiment with 7 sell transactions and 0 buys

Compare Another Pair

NRIX vs OMCL: Head-to-Head Comparison

This page compares Nurix Therapeutics, Inc. (NRIX) and Omnicell, Inc. (OMCL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile